<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394627</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002054</org_study_id>
    <nct_id>NCT01394627</nct_id>
  </id_info>
  <brief_title>Hypoglycemia and the Mineralocorticoid Receptor</brief_title>
  <acronym>HypoMR</acronym>
  <official_title>Hypoglycemia and the Mineralocorticoid Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Wood Johnson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at whether blockade of the mineralocorticoid receptor
      will result in changes in the cardiovascular and inflammatory response to hypoglycemia. We
      are also looking at the effect of hypoglycemia on fMRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of ongoing hypoglycemia on cardiovascular autonomic function is unclear and the
      focus of this protocol. In our preliminary studies, the investigators demonstrated that
      baroreflex sensitivity is impaired during hypoglycemia in healthy individuals. Treatment
      with eplerenone (200mg total administered in two doses in the 15 hours prior to the
      hypoglycemic clamp) prevented this impairment.

      The study is based on the overarching hypothesis that hypoglycemia leads to increases in
      aldosterone/mineralocorticoid receptor (MR) activity and increased cardiovascular injury.

      This study will address the following Specific Aims:

      To test the hypothesis that MR blockade will reduce the adverse effects of hypoglycemia on
      inflammation and on autonomic control of cardiovascular function.

      The investigators will determine the effects of hypoglycemia (50 mg/dl for 2.0 hours) on the
      blood inflammatory factor interleukin-6 levels, on cardiovascular autonomic function
      (baroreflex sensitivity and heart rate variability) and on arrhythmia risk (microvolt T-wave
      alternans (MTWA)) in each subject under two conditions - pretreatment with MR blockade
      (eplerenone) and pretreatment with placebo.

      To investigate the role of hypoglycemia on fMRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Cardiovascular Autonomic Function</measure>
    <time_frame>Baseline and 2 hours after hypoglycemia</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Inflammation</measure>
    <time_frame>Baseline and 2 hours after hypoglycemia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fMRI</measure>
    <time_frame>Baseline and after exposure to hypoglycemia</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>hypoglycemia of 50 mg/dl plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>100mg x 2</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Males and females age 18 to 40 years

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Menopause

          -  Any medical condition other than treated hypothyroidism.

          -  Alcoholism

          -  Active tobacco use

          -  In all subjects, any individuals on oral, injected, inhaled or topical
             corticosteroids within the last year or oral contraceptives within the past 3 months
             will be excluded.

          -  Use of medications other than physiological thyroxine replacement

          -  Serum potassium &gt;5.0 mmol/L

          -  Estimated GFR &lt; 60 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajaykumar D Rao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail K Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajaykumar D Rao, MD</last_name>
    <phone>617-732-8315</phone>
    <email>adrao@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gail K Adler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 6, 2015</lastchanged_date>
  <firstreceived_date>July 11, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gail Kurr Adler</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
